KR20150062207A - Compositions for Alleviating, Preventing or Treating Pain Comprising Harapagophytum procumbens and Acanthopanax senticosus Extracts as Active Ingredients - Google Patents

Abstract

The present invention provides a composition containing, as active ingredients, Harpagophytum procumbens and Acanthopanax senticosus extracts for alleviating, preventing, or treating a pain. A composition of the present invention represents effects in alleviating and treating an evoked pain and in preventing a pain by injecting to an object before evoking the pain. The composition of the present invention significantly represents a pain alleviating effect through an oral administration but not through a method such as an intravenous injection or a skin application, etc. The composition of the present invention having the same properties has a high applicability to food.

Description

(Compositions for Alleviating, Preventing or Treating Pain Comprising Harapagophytum procumbens and Acanthopanax senticosus Extracts as Active Ingredients), a composition for preventing, alleviating,

The present invention relates to a composition for alleviating, preventing or treating pain comprising a combination of a root canal and an astringent complex as an active ingredient.

Currently, analgesics such as aspirin and tylenol are the mainstream analgesics, and in the case of severe pain, most of the morphine drugs are used. Javelin Pharmaceuticals, a specialist in pain medicine, is developing a new pain-relieving drug, and its roots, which show analgesic effects equivalent to intravenous morphine for the treatment of pain after severe surgery, Rylomine was developed. In addition, the first painkiller "Prialt" developed by Elan, an Irish pharmaceutical company, was launched in the UK.

Chronic malignancies As well as benign pains and aging society, patients with degenerative arthritis and back pain-related diseases are on the rise every year. However, existing opioid preparations such as morphine have limited use due to drug action in the general population. Much more is expected. In addition, there is a great demand for the development of analgesics for pain that does not respond to existing analgesic drugs, and because of the narcotic and serious side effects of conventional opioids, which are known to have a relatively high analgesic effect, It is necessary to develop natural resources that have no side effects and have analgesic effect.

Harpagophytum procumbens , also known as the devil's claw, is also known as the Atta Tava or Grapple. It is a plant native to southern and southern Africa, and has long been used by African injectors and medical practitioners. (A.Duke, 1985; Bradley P, 1992; Blumenthal M, 1992), which has been used for the treatment of trauma, menstrual disorders, birth defects, digestive disorders and arthritis in Africa because of its bitter taste and bitter taste, 1998; Lanhers MC, 1992; Costa De Pasquale R, 1985).

Gasiohgapi (Acanthopanax senticosus) has an elongated stem has a thorn in full in Acanthopanax (Acanthopanax) plants distributed in the highlands, such as the Korean Peninsula and Japan, China and Siberia (National College of Oriental Medicine, Professor herbalism, 1994). It has been reported that eleutheroside species isolated from Rhizoctonia sp. Have been reported to have activity as an adaptogen, that is, an excellent activity for bio-adaptability and fatigue recovery against physicochemical external stress (Brekhman & Dardymov 1969) (Davydov and Krikorian, 2000). (Jung et al., 2007), anti-inflammatory effects (Jung et al., 2001), anti-allergic activity (Yoon et al., 2002) Studies such as antioxidant effects (Lin et al., 2008), immunomodulatory effects (Schmolz et al., 2001), liver function stimulation (Choi et al., 2006) and neuroprotective effects (Bu et al, 2005) It is progressing.

Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.

The inventors of the present invention have sought to develop a safe material, particularly a plant-derived material, capable of effectively relieving pain, and as a result, it has been found out that the combined extract of Tansu root and Rhizoma root is very effective for alleviating, preventing or treating pain , Thereby completing the present invention.

Accordingly, an object of the present invention is to provide a composition for alleviating, preventing or treating pain.

Another object of the present invention is to provide a food composition and a pharmaceutical composition for alleviating, preventing or treating pain.

Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention and claims.

According to one aspect of the present invention, there is provided a composition for alleviating, preventing or treating pain comprising an extract of the combination of Harappagophytum procumbens and Acanthopanax senticosus as an active ingredient.

The inventors of the present invention have made efforts to develop a safe material, particularly a plant-derived material, capable of effectively relieving pain, and as a result, it has been found that the complex extracts of Tansu root and Ganoderma lucidum are very effective in alleviating, preventing or treating pain .

The composition of the present invention is very effective for alleviating, preventing or treating pain.

As demonstrated in the following examples, when the compositions of the present invention were administered to an animal prior to skin incision surgery, pain sensitivity at the surgical site was reduced. In addition, the present invention relates to a combination of a root canal root and a root canal root extract.

The composition of the present invention exhibits remarkable pain relieving effect not only by intravenous injection or skin application but also by oral administration. The composition of the present invention having such characteristics can be applied to foods well.

The composition of the present invention not only alleviates and treats the pain generated, but also has an effect of preventing pain when administered to a subject before pain occurs.

Various extracting solvents can be used in the case of obtaining the combined root and root ganglioside extracts used in the composition of the present invention by treating the root and root gangliosides with an extraction solvent. According to the present invention, a polar solvent or a non-polar solvent can be used. Suitable polar solvents are (i) water, (ii) alcohols (preferably methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, 1-pentanol, Or ethylene glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMFO) and (v) dimethyl sulfoxide (DMSO). Suitable nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1- But are not limited to, pentane, 1-chlorobutane, 1-chloropentane, o -xylene, diisopropyl ether, 2- chloropropane, toluene, 1- chloropropane, chlorobenzene, benzene, diethyl ether, diethylsulfide, Methane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and THF.

According to an embodiment of the present invention, the extraction solvent used in the present invention may be selected from the group consisting of (a) water, (b) an anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, (E) ethyl acetate, (f) chloroform, (g) butyl acetate, (h) 1,3-butylene glycol, (i) hexane, and (j) Diethyl ether. In another embodiment of the present invention, the extract of the present invention is obtained by treating water, ethanol, or a combination thereof, with water and water. According to a specific embodiment of the present invention, the extract of the present invention is obtained by treating 40 to 80 vol% of grain alcohol in the root and the throat.

The present invention also provides a method of preparing a compound of the present invention and a method of preparing the same.

As used herein, the term " extract " means that it is used in the art as a crude extract as described above, but broadly includes fractions obtained by further fractionating the extract. That is, the combined extracts of Tansu and Rhizome include not only those obtained by using the above-mentioned extraction solvent but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The fraction obtained by the purification method is also included in the mixed root and root extract of the present invention.

As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve the efficacy or activity of the following combined root and root extracts. Since the composition of the present invention includes extracts obtained from the root and root galls, which are natural plant materials, there is no adverse effect on the human body even when administered in an excessive amount. Therefore, the quantitative upper limit of the compositions of the present invention, As shown in FIG.

The term " pain " is used in the present invention in its broadest sense and includes acute and chronic pain such as pain ache and pain, such as somatic pain and visceral pain; Pain, pain, inflammatory pain, dysfunctional pain, idiopathic pain, superficial pain, deep pain, itching, neuropathic pain such as centrally generated pain and peripherally generated pain, migraine, and cancer pain.

The term " nociceptive pain " is used to include all pain caused by noxious stimuli that may or may damage nervous tissues and may include ben, cut, bruise, fracture, bone pain, bone fracture, crush injury, burn, and similar wounds. Pain receptors for tissue damage (nociceptors) are mostly located in the skin, musculoskeletal or internal organs.

The term " somatic pain " is used to indicate pain that occurs in bones, joints, muscles, skin or connective tissue. This type of pain is typically very localized.

The term " visceral pain " is used herein to refer to any or all of the organs such as respiratory, gastrointestinal tract and pancreas, urinary tract and reproductive organs, Used to indicate pain that occurs. Embolic pain includes pain induced by tumor involvement of the organ capsule. Other types of visceral pain are typically caused by occlusion of the hollow viscus, characterized by intermittent cramping and severe local pain. Embolic pain may be associated with inflammation, as in the case of cystitis or reflux esophagitis.

The term " inflammatory pain " includes pain associated with active inflammation, which may be caused by trauma, surgery, infection, and autoimmune diseases.

The term " superficial pain "refers to the pain sensed by the skin segments of the nerves of the dorsal root, and is a direct pain to feel the pain at the point of stimulation.

The term " deep pain "refers to pain originating from the deep organs, which varies in character and degree depending on the nature of the tissue. Particularly sensitive areas of pain include tendons, In general, deep pain is a dull feeling, spreads to the surrounding area, and the area to be felt is wide. The pain of the deep part or the internal organs is complex, and it is difficult to locate the pain rather than the surface pain, And problems such as an increase in blood pressure also occur.

The term " neuropathic pain " is used herein to denote pain resulting from sensory input of abnormal processing by the peripheral or central nervous system resulting from disturbance of the peripheral or central nervous system.

The term " procedural pain " refers to pain that occurs in internal medicine, dentistry, or surgery, and the procedure is usually scheduled or associated with acute trauma.

The term " itch " is used herein in its broadest sense and refers to all types of itchy, stinging sensations of acute intermittency and persistence that can be generally described by limiting to local. The itch may be due to idiopathic, allergic, metabolic, infectious, drug-induced, liver, kidney disease or by cancer. "Pruritus" is severe itching.

&Quot; Patient " means any animal. In one embodiment of the invention, the patient is a human. Other animals that may be treated using the composition of the invention include non-human primates (e.g., monkeys, gorillas, chimpanzees), livestock (e.g., horses, pigs, goats, rabbits, sheep, cows, llamas) But are not limited to, animals (such as guinea pigs, rats, mice, lizards, snakes, dogs, cats, ornamental fish, hamsters and birds).

Neuropathic, inflammatory, and nociceptive pain are different in etiology, pathophysiology, diagnosis and treatment. Acupuncture pain occurs in response to activation of nociceptors by a specific subset of peripheral sensory neurons, that is, intense or harmful stimuli. Acute water-soluble pain is a generally sensitive, self-limiting, and provides a biological function of protection by acting as a warning of potential or ongoing tissue damage. Pain Acceptable pain is typically very limited to locality. Examples of painful painful pain include, but are not limited to, traumatic or surgical pain, labor pain, sprains, bone fractures, burns, bumps, but are not limited to, bruises, injections, dental procedures, skin biopsies and obstructions.

Inflammatory pain is associated with joints such as postoperative, post-traumatic pain, arthritis (rheumatoid or osteoarthritis) pain, and axial low back pain. ), Pain associated with damage to muscles and tendons, or pain when there is a tissue injury or inflammation.

Pain In contrast to water-soluble pain, neuropathic pain is depicted as actual "burning," "electric," "tingling," or "shooting" do. Neuropathic pain is often defined as chronic allodynia (defined as pain due to stimuli that do not cause a normal pain response, such as a mild touch) and hyperalgesia (a high susceptibility to normal pain stimuli ) And may last for months or years after apparent healing of any damaged tissue.

The composition of the present invention may be provided as a pharmaceutical composition.

When the composition of the present invention is manufactured from a pharmaceutical composition, it includes not only a root-shell root extract and astringent complex extract as an active ingredient, but also a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, the composition can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, or the like.

The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient, Usually, a skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-100 mg / kg.

The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

The composition of the present invention can be provided as a food composition.

When the composition of the present invention is prepared with a food composition, it contains not only the root extract and the complex extract of Astragalus and Thalassaides as an active ingredient, but also components that are ordinarily added at the time of food production. Examples thereof include protein, carbohydrate, fat, And flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be used as flavorings.

For example, when the food composition of the present invention is prepared as a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, etc., Can be included.

The features and advantages of the present invention are summarized as follows:

(a) The present invention provides a composition for alleviating, preventing, or treating pain comprising an extract of Tansu root and Rhizoma root as an active ingredient.

(b) The composition of the present invention not only alleviates and treats the pain generated, but also has the effect of preventing pain when administered to a subject before pain occurs.

(c) The composition of the present invention exhibits remarkable pain relieving effect not only by intravenous injection or skin application but also by oral administration, and the composition of the present invention having such characteristics is highly applicable to food.

FIG. 1 shows the result of measuring the pain sensitivity of the surgical site 5 hours and 24 hours after the skin incision was performed by orally administering 150 mg / kg of a root canal extract to an experimental animal through mechanical allodynia evaluation.
Control group (n = 10) and root canal extract (150 mg / kg) group (n = 10).
FIG. 2 shows the results of measurement of the number of times of ultrasonic wave generation of the 22-27 kHz lunar group of the experimental animals after 6 hours and 24 hours after the skin incision operation was performed orally after administering 150 mg / kg of the watery root extract to the experimental animals.
Control group (n = 10) and root canal extract (150 mg / kg) group (n = 10).
FIG. 3 shows the result of measuring the pain sensitivity at the surgical site 5 hours and 24 hours after the skin incision was performed by oral administration of 150 mg / kg of the extract of Aspergillus oryzae to the experimental animals through mechanical allodynia evaluation.
Control group (n = 10), Acanthopanax senticosus extract (150 mg / kg) group (n = 10).
FIG. 4 shows the results of measurement of the number of times that the experimental animals were exposed to ultrasonic waves of the 22-27 kHz lunar counterpart after 6 hours and 24 hours after the oral administration of 150 mg / kg of the extract of Aspergillus oryzae to the experimental animals.
Control group (n = 10), Acanthopanax senticosus extract (150 mg / kg) group (n = 10).
FIG. 5 shows the result of measuring the pain sensitivity of the surgical site by mechanical allodynia evaluation after 5 hours and 24 hours after the skin incision operation, orally administered 300 mg / kg of the combined extract of Tianyu and Ganoderma lucidum to the experimental animals.
(N = 12), ** p < 0.01 (n = 12), control group
FIG. 6 shows the results of the oral administration of 300 mg / kg of the combined extract of Tansu root and Ganoderma lucidum to the experimental animals, and the number of times that the animals were exposed to 22-27 kHz ultrasonic waves after 6 and 24 hours Results.
(N = 12), control group (n = 12), turpentine + astringent complex extract (300 mg / kg)

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Example

Experimental Method

Sample extraction

Natural herbal extracts were purchased from Kangdong (Korea), located in Kyungdong market, and were extracted as raw materials before extraction. After adding 70 vol% of alcohol per 100 g of raw materials, the mixture was extracted at 80 ℃ for 4 hours. The filtrate and residue extracts were combined, filtered and concentrated under reduced pressure. All the extracts were filtered and concentrated under reduced pressure, lyophilized and powdered for use in the experiment.

Experimental animal

Sprague-Dawley (SD) rats (200-250 g, male) were purchased from Samtako Co., Ltd. and used for experiments for one week in an experimental animal breeding box. The animals were fed under the conditions of temperature 22 ± 1 ℃, humidity 55 ± 5%, day and night cycle (12 hours day / 12 hours night), illumination 300 lux, feed and water free. All animals were managed by the KFRI-IACUC (National Food Research Institute, Laboratory Animal Care and Use Committee) guidelines.

Sample preparation and administration

Body weight was measured for normal animals after the adaptation, and the experimental group was randomly selected. The animal identification of the experimental animals was carried out using the pigment coloring method. And 70% ethanol extracts were prepared by dissolving and suspending the extracts in an appropriate concentration in the second distilled water. (30 mg / kg / day) for 30 min before surgery. The dose of 150 mg / kg / 5 ml of turmeric, 150 mg / kg / 5 ml of goosomotor and 300 mg / kg / (Po) and the same amount of secondary distilled water was administered orally (po) 30 minutes before the operation.

Skin incision model

A rat skin incision model was proposed by Brennan (Brennan, 1996). Generally, postoperative pain is thought to be a form of acute pain, and the incision model of the rat is thought to be similar to the postoperative pain state in humans. SD male rats (200-250 g) were anesthetized using pentobarbital and the left footpad was disinfected with 10% povidone solution and then started at a distance of 0.5 cm from the tip of the heel. The skin and fascia Were incised with a No. 11 surgical knife. The plantar muscle (plantar muscle) of the incision was lifted with a forceps to separate a length of 1 cm. At both ends of the vertical direction, the foot muscles were lifted carefully to avoid falling, and the bleeding was performed by gently pressing the incision. The fascia and skin of the bleeding incision site were closed with nylon 4-0 suture and disinfected with 10% povidone solution. After surgery, antibiotic ointment was applied to prevent infection and transferred to a cage for restoration. Animals that developed fever during the observation period, or sutures and edema were excluded from the study.

Von frey filament test

A method for measuring the degree of mechanical allodynia after animal pain modeling has been described by Chaplan et al. (Chaplan et al., 1994). The rats were placed in an acrylic box mounted on a wire mesh test bench with a mesh size of 2 x 2 mm and adapted for at least 15 minutes. When the movement of the rats was quiet, the continuous whitening prefilament (Stoelting, USA) (Mechanical withdrawal threshold (g)). The filament is contacted vertically on the left footpad and maintained for 5-6 seconds, and the rat is regarded as showing a positive avoidance reaction or showing a positive response if it immediately flaps or licks the foot as the hairs are released. Stimulate with weak filaments when stimulating positive filaments from central filaments, stimulating with weak filaments, and stimulating with strong filaments. The minimum stimulation size for positive reactions should be considered as a threshold, and the upper limit should not be applied when there is no reaction even at 15 g or more.

Ultrasonic vocalization calls

Rats produce ultrasound when they are in pain, distress, atrophy or stress, and their ultrasound range is reported to be 22-27 KHz (Portfors, 2007). To determine the degree of pain at 6 and 24 hours postoperatively, we used ultrasonic waves (22-27 KHz) when we felt pain using USV measurement system (Sonotrack, ver 1.5.0, Metris, ), And ultrasonic voice was measured. The rats were placed in an acrylic box capable of measuring ultrasound, stabilized for 15 minutes, and ultrasonic measurement was conducted for 10 minutes.

Experiment result

Estimation of pain relief at 150 mg / kg of tubular muscle by evaluation of mechanical allodynia

After 5 hours and 24 hours (POD1) of skin incision, mechanical allodynia evaluation was performed to determine the pain sensitivity at the surgical site. As a result, the mechanical withdrawal threshold (g) of the control group after 5 hours of operation was 0.827 ± 0.213 (g), and the power of the pain felt at the cephalic 150 mg / kg group was 1.300 ± 0.277 (g) Were not statistically significant but increased. In addition, the magnitude of the force that felt pain was 1.500 ± 0.521 (g) in the 150 mg / kg group of the tineaurous compared with 1.033 ± 0.233 (g) in the control group after 24 hours of operation (POD1) But did not increase.

Confirmation of pain relief effect of 150 mg / kg of turpentine using ultrasound sound

The ultrasound lunar lunar band (22-27 kHz), which was induced when the animal was experiencing pain after 6 hours and 24 hours (POD1) of skin incision, was measured and the number of times was quantified to evaluate the pain relief effect. After 6 hours of operation, USV call measurements showed 14.333 ± 6.141 (calls) in the tropic 150 mg / kg group compared to the control group 18.667 ± 3.451 (calls), which was not statistically significant but decreased. In addition, after the 24-hour operation (POD1), it was recorded that the circulation 150 mg / kg group was 15.667 ± 4.667 (calls) compared with the control group 17.833 ± 4.086 (calls).

Assessment of pain relief effect of 150 mg / kg of astringent gum by mechanical allodynia evaluation

After 5 hours and 24 hours (POD1) of skin incision, mechanical allodynia evaluation was performed to determine the pain sensitivity at the surgical site. As a result, the mechanical strength (g) value of the control group after 5 hours of operation was 0.733 ± 0.205 (g) and 1.033 ± 0.250 (g) of the 150 mg / kg group of viscose was statistically significant But increased. In addition, the magnitude of the force that felt pain was 1.233 ± 0.280 (g) in the group of 150 mg / kg of astragalus, compared with 0.900 ± 0.144 (g) in the control group after 24 hours of operation (POD1) But did not increase.

Determination of pain relief effect of caustic soda 150 mg / kg by ultrasonic vocal sound

The ultrasound lunar lunar band (22-27 kHz), which was induced when the animal was experiencing pain after 6 hours and 24 hours (POD1) of skin incision, was measured and the number of times was quantified to evaluate the pain relief effect. After 6 hours of operation, the USV call measurement was recorded as 9.667 ± 3.313 (calls) in the asthma group of 150 mg / kg compared with the control group of 11.500 ± 3.713 (calls). In addition, after 24 hours of operation (POD1), it was recorded as 12.333 ± 5.566 (calls) in the 150 mg / kg group of astragalus, compared with 14.833 ± 4.316 (controls) in the control group.

Evaluation of pain relief effect of 300 mg / kg complex of Tansu-ga + gasshiopa complex by evaluation of mechanical allodynia

After 5 hours and 24 hours (POD1) of skin incision, mechanical allodynia evaluation was performed to determine the pain sensitivity at the surgical site. As a result, after 5 hours of operation, the magnitude of the force felt by the control group (g) was 2.950 ± 0.15 (g) in the turbinate + (P <0.01), respectively. In addition, the mechanical evasion threshold value (g) of the control group after 24 hours of operation (POD1) was 3.167 ± 0.738 (g) in the case of 300 mg / (P <0.01), respectively.

Confirmation of pain relief effect of 300 mg / kg complex of Tansu-ga +

The ultrasound lunar lunar band (22-27 kHz), which was induced when the animal was experiencing pain after 6 hours and 24 hours (POD1) of skin incision, was measured and the number of times was quantified to evaluate the pain relief effect. After 6 hours of operation, the USV call measurements showed a statistically significant decrease (p <0.05) in the TMC + 300 mg / kg group compared with the control group of 17.917 ± 3.953 (calls) . In addition, it was statistically significant (p <0.05) decreased by 244 hours (POD1) and 6.417 ± 2.241 (calls) in the group of 300 mg / kg of TCE compared with 19.250 ± 4.236 (calls) of the control group.

conclusion

The present invention demonstrates the effect of the combined root canal plus astragalus complex on relieving pain in an animal model of skin incision pain. In particular, in the evaluation of mechanical allodynia, the 300 mg / kg complex of Tansu root + astragalus showed the effect of 73.80% compared to the control, which is more advanced than the double dose of each single extract. In addition, in the ultrasonic voice test, 300 mg / kg complex of Tansu root + astragalus showed 69.47% of the effect compared with the control, which is superior to each double extract of each single extract. Accordingly, the present invention relates to a composition comprising an extract of Tansu root + astragalus complex as an active ingredient, and exhibits the effect of preventing, alleviating or treating pain.

references

James A. Duke. Handbook of Medical Herb. florida CRC Press. (1985)

Bradley P. British Herbal Compendium (I). England: British Herbal Medicine Association (1992)

Blumenthal M. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, Integrative Medicine Communications (1998)

Lanhers MC. Planta Med. 58 (2): 117-123 (1992)

Costa De Pasquale R et al., J Ethnopharmacol. 13 (2): 193-199 (1985)

Professor of herbal medicine at Korea National University of Medicine. Herbal medicine. Young Lim Corporation. p283 (1994)

Brekhman II, Dardymov IV. Annu Rev Pharmacol 9: 419-430 (1969)

Davydov M, Krikorian AD. J Ethnopharmacol 72: 345-393 (2000)

Dowling EA et al., Med Sci Sports Exerc 28: 482-489 (1996)

Gaffney BT, Hugel HM, Rich PA. Med Hypotheses 56: 567-572 (2001)

Yoon TJ et al., Korean J Food Sci Technol 34: 518-523 (2002)

Jung SM et al., Arthrit Res Ther 9: R64 (2007)

Lin QY et al., Phytother Res 22: 740-745 (2008)

Schmolz MW et al., Phytother Res 15: 268-270 (2001)

Choi JS et al., Biol Pharm Bull 29: 306-314 (2006)

Y et al., Phytotherapy research. 19: 167-169 (2005)

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (6)

A composition for alleviating, preventing or treating pain comprising an extract of Harappagophytum procumbens and Acanthopanax senticosus as an active ingredient.
The composition according to claim 1, wherein the combined root and root extract is obtained by treating water, methanol, ethanol or a combination thereof with a root and a root.
The composition of claim 1, wherein the composition is a composition for preventing pain.
The method of claim 1, wherein the pain is selected from the group consisting of somatic pain, visceral pain, inflammatory pain, dysfunctional pain, idiopathic pain, neuropathic pain, superficial pain, deep pain, itching, migraine and cancer pain.
The composition of claim 1, wherein the composition is a pharmaceutical composition.
A composition for alleviating or preventing pain comprising an extract of Tansu Root and Ganoderma lucidum as an active ingredient.

Images